Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
HMGCR 3156 CERIVASTATIN CHEMBL1477 inhibitor PharmGKB, GuideToPharmacologyInteractions, DrugBank, TTD 11057870, 11752352, 11448925, 11470741, 10740137, 10193776
HMGCR 3156 SIMVASTATIN CHEMBL1064 inhibitor PharmGKB, TTD, TEND, TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, ChemblInteractions 12518039, 12852453, 11752352, 12671581, 12433810, 12677170
HMGCR 3156 PRAVASTATIN CHEMBL1144 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
HMGCR 3156 CHEMBL160102 CHEMBL160102 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL1205894 CHEMBL1205894 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL489540 CHEMBL489540 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 ROSUVASTATIN CALCIUM CHEMBL1744447 inhibitor ChemblInteractions
HMGCR 3156 CHEMBL1161866 CHEMBL1161866 DrugBank 15152097, 17139284, 17016423, 15755483, 14511985
HMGCR 3156 CHEMBL1163804 CHEMBL1163804 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 ROSUVASTATIN CHEMBL1496 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
HMGCR 3156 CHEMBL101497 CHEMBL101497 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL400874 CHEMBL400874 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL318707 CHEMBL318707 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 FLUVASTATIN SODIUM CHEMBL2218894 inhibitor ChemblInteractions
HMGCR 3156 ATORVASTATIN CALCIUM CHEMBL393220 inhibitor ChemblInteractions
HMGCR 3156 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A CHEMBL1794644 DrugBank 17139284, 17016423
HMGCR 3156 MEGLUTOL CHEMBL50444 DrugBank 17139284, 17016423
HMGCR 3156 PROCAINE CHEMBL569 DrugBank
HMGCR 3156 ATORVASTATIN CHEMBL1487 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
HMGCR 3156 MEVASTATIN CHEMBL54440 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL115307 CHEMBL115307 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL228955 CHEMBL228955 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL1165259 CHEMBL1165259 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL412295 CHEMBL412295 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CERIVASTATIN SODIUM CHEMBL1200563 inhibitor ChemblInteractions
HMGCR 3156 PITAVASTATIN CALCIUM CHEMBL1237061 inhibitor ChemblInteractions
HMGCR 3156 ASPIRIN CHEMBL25 inhibitor TTD
HMGCR 3156 LAROPIPRANT CHEMBL426559 inhibitor TTD
HMGCR 3156 LOVASTATIN CHEMBL503 inhibitor PharmGKB, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 12082550, 12204108, 12172803, 11752352, 12369143, 19249983, 12405293, 12214063
HMGCR 3156 COENZYME_A CHEMBL1213327 DrugBank 17139284, 17016423
HMGCR 3156 CHEMBL1161862 CHEMBL1161862 DrugBank 17139284, 17016423
HMGCR 3156 LAPAQUISTAT ACETATE CHEMBL435224 DrugBank
HMGCR 3156 CHEMBL133434 CHEMBL133434 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 VALPROIC ACID CHEMBL109 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL161829 CHEMBL161829 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 VALERIC ACID CHEMBL268736 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL228528 CHEMBL228528 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 CHEMBL483819 CHEMBL483819 inhibitor GuideToPharmacologyInteractions
HMGCR 3156 PRAVASTATIN SODIUM CHEMBL690 inhibitor ChemblInteractions
HMGCR 3156 PITAVASTATIN CHEMBL1201753 inhibitor TdgClinicalTrial, TEND, DrugBank 22472908

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
HMGCR rs17244841 A fluvastatin efficacy no Allele A is not associated with response to fluvastatin in people with renal transplantation as compared to allele T. 17563401 699638701
HMGCR rs17671591 CT + TT atorvastatin efficacy yes Patients with the CT or TT genotype had a greater drop in low-density lipoprotein cholesterol (LDL-C) as compared to those with the CC genotype; no significant difference in basal levels or post-treatment levels were seen. Additionally, those with the CT or TT genotype had a greater increase in high-density lipoprotein cholesterol (HDL-C) as compared to those with the CC genotype; those with the CT or TT genotype also had a lower basal level of HDL-C as compared to those with the CC genotype. No significant differences in basal levels, post-treatment levels, or % change were seen when considering total cholesterol (TC) or triglycerides (TG). 10 mg/day atorvastatin for 4 weeks. Genotypes CT + TT is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC. 26408409 1447674959
HMGCR rs3846662 AA hmg coa reductase inhibitors efficacy yes The percentage reduction in LDL-cholesterol upon statin treatment was significantly decreased in women with the AA genotype Genotype AA is associated with decreased response to hmg coa reductase inhibitors in women with familial hypercholesterolemia as compared to allele G. 26466344 1446907782
HMGCR rs17238540 T fluvastatin efficacy no Allele T is not associated with response to fluvastatin in people with renal tranplantation as compared to allele G. 17563401 699639070
HMGCR rs17238540 GT pravastatin efficacy no as measured by decreases in LDL-cholestrol. No significant association was seen with response. Described as SNP29 in the HMGCR gene. Genotype GT is not associated with response to pravastatin as compared to genotype TT. 16103896 699639067
HMGCR rs17238540 G pravastatin efficacy no PROSPER study. Baseline Lipid Values, LDL-C lowering response,trial CHD and CVD outcomes were measured. 40 mg/day pravastatin. There was also no association with baseline lipid level or baseline CVD. Allele G is not associated with response to pravastatin in people with Vascular Diseases as compared to allele T. 18261733 769152897